Clinical Trials Logo

Clinical Trial Summary

The goal of this multicentre, observational study on mpox in infants, children and adolescents is to increase knowledge about mpox infection and its associated disease in infants, children and adolescents. This will be done through the development of a harmonized system that will allow standard collection of information on demographics, clinical symptoms, clinical course, treatments and outcomes. The study will be carried out in three potential phases: Phase 1 entails the rapid development of an online paediatric registry collecting anonymised data from routine care on infants, children and adolescents with laboratory-confirmed mpox virus infection. If warranted, the study will proceed to Phase 2, an enhanced observational study of children and adolescents with confirmed mpox virus infection, if more detailed prospective data collection would aid the public health response. There is also the potential to initiate Phase 3, comprising of nested sub-studies to investigate specific research questions in this population.


Clinical Trial Description

The primary objective of this multicentre observational study is to use a harmonised data system for the standard data collection and analysis to describe the presentation, clinical course and outcomes of laboratory-confirmed mpox virus infection in infants, children and adolescents by: 1. monitoring the temporal and geographical distribution of mpox infection in the paediatric and adolescent population, including in specific paediatric/adolescent groups, such as those with underlying conditions or with congenital mpox; 2. describing the epidemiology and clinical presentation of the disease, including outcomes of treatment administered as part of routine care; 3. describing high risk populations , including identifying factors associated with severe disease and death. Phase 1 consists of the rapid development of an online registry for standard collection of data on infants, children and adolescents with laboratory-confirmed mpox infection, including adolescent girls who acquired mpox in pregnancy, and infants who acquired mpox through vertical transmission. All data will be fully anonymised, allowing rapid implementation in many countries without the need for ethics approval, where applicable. If additional data collection would aid the public health response, the investigators might additionally include a second phase (Phase 2) of the project, with the aim to implement an enhanced prospective observational study of children and adolescents with confirmed mpox infection. This part of the project, if activated, will be a consented study collecting detailed data over the course of the disease. Phase 3: initiation of nested sub-studies within the consented observational study (Phase 2) to investigate specific research questions in this population, including collection of samples, where necessary, for analysis and/or storage in a biobank. Each sub-study will require its own protocol and informed consent. The database, networks and systems developed within Phases 1 to 3 will be flexible and designed to be readily adapted to data collection for other emerging and re-emerging infections in children. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05947786
Study type Observational
Source PENTA Foundation
Contact Giorgia Dalla Valle
Phone 393783022748
Email giorgia.dallavalle@pentafoundation.org
Status Recruiting
Phase
Start date March 17, 2023
Completion date July 31, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05512949 - Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine Phase 2
Completed NCT05976100 - Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years Phase 1
Recruiting NCT05988203 - A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines Phase 1
Terminated NCT05567939 - Clinical, Virological, Immunological, Psychosocial and Epidemiological Consequences of Human Monkeypox Virus (ProMPX)
Active, not recruiting NCT05562323 - Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
Recruiting NCT05534984 - Study of Tecovirimat for Human Monkeypox Virus Phase 3
Not yet recruiting NCT05784038 - Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
Not yet recruiting NCT05745987 - Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT Phase 4
Recruiting NCT05879965 - Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
Completed NCT03745131 - Cohort Study of Healthcare Workers Receiving Imvanex®
Recruiting NCT05559099 - Tecovirimat for Treatment of Monkeypox Virus Phase 2
Completed NCT05846243 - Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years Phase 2/Phase 3
Not yet recruiting NCT05629299 - Pilot Study to Detect Monkey Pox Virus in Sperm: POXSPERM N/A
Recruiting NCT05654883 - New York City Observational Study of Mpox Immunity
Completed NCT05762523 - Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years Phase 1
Recruiting NCT05597735 - Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease Phase 3
Recruiting NCT05734508 - Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC Phase 4
Active, not recruiting NCT05740982 - A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox Phase 2
Recruiting NCT06045923 - Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
Completed NCT05476744 - Viral Clearance and Epidemiological Characteristics in Patients With Monkeypox